Glucocorticoids and B-cell targeting therapies are the cornerstones of IgG4 disease treatment, according to data presented at ...
MedPage Today on MSN
Another B-Cell Drug for Lupus Hits the Mark
Phase III results put obinutuzumab in line for approval ...
Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...
The announcement is anchored by a study published in Biomacromolecules (American Chemical Society, 2026), conducted by MindWalk in a grant-funded collaboration with Eindhoven University of Technology ...
SAVANNAH, Georgia — Inebilizumab, a first-in-class anti-CD19 B-cell depleting agent, demonstrated both safety and superior efficacy compared with placebo in patients with seropositive generalized ...
First implementation of artificial intelligence empowered all-in-one radiotherapy workflow for nasopharyngeal carcinoma. Longitudinal tracing of on-treatment plasma Epstein-Barr virus DNA as a ...
Ultrasensitive detection of circulating tumor DNA can improve clinical outcomes in aggressive B-cell lymphomas by identifying measurable residual disease. Defining remission is challenging due to ...
However, details of the intervening steps, as researchers have learned in the past 65 years, are quite complex — certain cells carry the flu antigen to the immune system, specific immune cells respond ...
The pleural effusion that was initially drained recurred after two weeks but subsequently resolved on follow‑up imaging as part of the patient’s response to chemotherapy. Repeat LDH measurement was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results